GTCbio and the advisory board would like to invite you to the 2017 Diabetes Summit to be held April 5-7, 2017 in Boston, MA. GTCbio’s Diabetes Summit encompasses the drug discovery and partnering aspects of diabetes in two separate consecutive conferences. Experts from industry and academia will discuss strategies to target Type 1 and Type 2 diabetes in presentations, panels and round-table discussions that highlight basic research novel therapeutic targets, translation to the clinic, devices and digital aids, funding and partnering trends, emerging technologies and other relevant topics.
Conference 1: 10th Diabetes Drug Discovery & Development Conference
- Going Back to the Basics – Street Light Effect
- Novel Therapeutic Targets & Strategies
- Translation to The Clinic: What’s in the Pipeline
Joint: Plenary Session :
- Where do We Stand with Stem Cell Therapy in Diabetes?
Conference 2: 7th Diabetes Partnering & Deal-Making Conference
- Devices and Digital Aids in Diabetes
- Panel: Treating Diabetes in 2020: Beyond Insulin, What?
- Panel: Current Trends and Future Projections for Investment
- Partnering and Licensing Opportunities
- Biotech Showcase: Emerging Pipelines
- Panel: Patient Entrepreneur
We look forward to seeing you at the conference!
The 2017 Advisory Committee
|2017 Advisory Board Members|
|Robert Geho, Diasome Pharmaceuticals Inc|
|Zan Fleming, Kinexum|
|Alan Cherrington, Vanderbilt|
|Nirja Patel, ALPCO Diagnostics|
|Vivek Shenoy, Renovo|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. We’re pursuing some of the most innovative areas in biomedical research emerging today without regard to therapeutic area/modality. Merck has hundreds of successful collaborations with companies, academic institutions, and other organizations. Learn more at www.merck.com/licensing.
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
CrownBio’s Cardiovascular and Metabolic Disease (CVMD) portfolio is a unique continuum of translational platforms that model human diseases such as diabetes, obesity, renal disease, NAFLD/NASH etc. These translational platforms help bridge the preclinical to clinical gap and enable our clients to take strategic go/no-go decisions in drug development.
Bachem provides comprehensive services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based APIs. The group has a global reach with more experience and know-how than any other company in the industry. Bachem. Pioneering Partner for Peptides